Background: Reports of resistance and intolerance to currently available antifungal agents
are increasing. Voriconazole is a broad-spectrum azole antifungal agent structurally derived …

The new triazole antifungal, voriconazole (Vfend®, Pfizer Ltd), was developed for the
treatment of life-threatening fungal infections in immunocompromised patients. The drug …

OBJECTIVE: To review the currently available information on the pharmacology,
pharmacokinetics, efficacy, adverse effects, drug interactions, and dosage guidelines of …

Voriconazole (VFEND®), a synthetic second-generation, broad-spectrum triazole derivative
of fluconazole, inhibits the cytochrome P450 (CYP)-dependent enzyme 14-α-sterol …

Voriconazole is a new antifungal agent that can be given orally and intravenously. It has
proven efficacy for treating candidosis and invasive aspergillosis as well as other mould …

OBJECTIVE: To review the pharmacology, in vitro susceptibility, pharmacokinetics, clinical
efficacy, and adverse effects of voriconazole, a triazole antifungal agent. DATA SOURCES …

Voriconazole is a new triazole antifungal agent structurally related to fluconazole, but with
improved potency and spectrum of activity. Voriconazole has good in vitro activity against …

Voriconazole is the first available second-generation triazole with potent activity against a
broad spectrum of clinically significant fungal pathogens, including Aspergillus, Candida …

The 1990s witnessed an expansion of the antifungal armamentarium to include 2 new azole
agents, fluconazole and itraconazole. These agents changed our approach to treating many …

Treatments for invasive fungal infections remain unsatisfactory. We evaluated the efficacy,
tolerability, and safety of voriconazole as salvage treatment for 273 patients with refractory …